St. Johns Investment Management Company LLC trimmed its position in Becton Dickinson and Co (NYSE:BDX) by 9.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,845 shares of the medical instruments supplier’s stock after selling 503 shares during the period. St. Johns Investment Management Company LLC’s holdings in Becton Dickinson and were worth $1,037,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Bank of Montreal Can increased its holdings in Becton Dickinson and by 25.5% during the 4th quarter. Bank of Montreal Can now owns 420,170 shares of the medical instruments supplier’s stock worth $89,941,000 after purchasing an additional 85,285 shares in the last quarter. Davis R M Inc. increased its holdings in Becton Dickinson and by 430.6% during the 4th quarter. Davis R M Inc. now owns 8,490 shares of the medical instruments supplier’s stock worth $1,817,000 after purchasing an additional 6,890 shares in the last quarter. Wendell David Associates Inc. increased its holdings in Becton Dickinson and by 1.3% during the 4th quarter. Wendell David Associates Inc. now owns 17,107 shares of the medical instruments supplier’s stock worth $3,662,000 after purchasing an additional 225 shares in the last quarter. Private Trust Co. NA increased its holdings in Becton Dickinson and by 12.1% during the 4th quarter. Private Trust Co. NA now owns 4,557 shares of the medical instruments supplier’s stock worth $975,000 after purchasing an additional 491 shares in the last quarter. Finally, YHB Investment Advisors Inc. increased its holdings in Becton Dickinson and by 5.0% during the 4th quarter. YHB Investment Advisors Inc. now owns 24,070 shares of the medical instruments supplier’s stock worth $5,152,000 after purchasing an additional 1,156 shares in the last quarter. 75.54% of the stock is owned by institutional investors and hedge funds.

Becton Dickinson and Co (NYSE:BDX) opened at $228.54 on Wednesday. Becton Dickinson and Co has a 12 month low of $169.19 and a 12 month high of $230.12. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The company has a market capitalization of $60,665.43, a P/E ratio of 49.15, a P/E/G ratio of 1.78 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter in the prior year, the business earned $2.12 earnings per share. Becton Dickinson and’s revenue for the quarter was down 2.0% on a year-over-year basis. equities analysts expect that Becton Dickinson and Co will post 10.66 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Investors of record on Friday, December 8th were paid a $0.75 dividend. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date was Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.31%. Becton Dickinson and’s dividend payout ratio is presently 64.52%.

A number of brokerages have commented on BDX. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Citigroup raised Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. KeyCorp began coverage on Becton Dickinson and in a report on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective for the company. Evercore ISI began coverage on Becton Dickinson and in a report on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective for the company. Finally, Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a report on Friday, December 29th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $230.20.

COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Shares Sold by St. Johns Investment Management Company LLC” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/becton-dickinson-and-co-bdx-shares-sold-by-st-johns-investment-management-company-llc/1810514.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.